Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial

Axel Grothey

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)65-66
Number of pages2
JournalCurrent Colorectal Cancer Reports
Issue number2
StatePublished - Apr 2009

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Cite this